The clinic says health history, goals, current meds, side effects and insurance coverage should all come up when picking a GLP-1 with your provider.
Recap by typeshit. Post by @physicianspremiere_weight on Instagram.
Fiscal.ai posted a chart comparing Lilly and Novo Nordisk and says Lilly is pulling ahead in the obesity drug market. Only the chart is shared, with no other detail.
Sam Stone mixed GLP-1 Daily Support powder into a smoothie daily and came away with stomach aches and doubts about what it does.
Dr Desmond Wai shares the Novo Nordisk news and notes the FDA cleared semaglutide for fatty liver disease in the US more than a year earlier.
A short personal check-in from a creator who tags her post with tirzepatide. No numbers or details beyond the update itself.
10:37
PBS NewsHour reports on the growing research into whether GLP-1 medications could help with addiction to alcohol and other drugs.
Pooling six trials with 3,459 adults, researchers saw bigger drops in weight, HbA1c and blood pressure at the higher dose. They flag small liver enzyme rises to monitor.
Loading…